A smallpox drug being developed jointly by St. Louis University and SIGA Technologies Inc. of New York City has passed another hurdle en route to human testing. The drug has shown promise in pre-clinical tests, said Mark Buller, a professor of molecular microbiology who’s leading the smallpox treatment research at SLU. Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.